A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Mean 24-hour IOP
研究概览
简要总结
The objective of this crossover, randomized, placebo controlled, double-masked study is to compare the short-term (12 weeks) mean 24-hour IOP control and safety of the new fixed combination (bimatoprost/timolol, BTFC) given PM with placebo once in the morning, versus BTFC given AM with placebo once in the evening versus bimatoprost given in the evening in patients with exfoliative glaucoma (XFG).
详细描述
PRIMARY STUDY OBJECTIVES
- To show that the mean 24-hour IOP control obtained with BTFC (morning or evening) is statistically better to that with bimatoprost monotherapy given once on the evening.
- To demonstrate that the fixed combination will provide a significantly better IOP control in the morning when dosed in the evening.
- To test whether the mean 24-hour IOP control obtained with BTFC given once in the evening may be statistically better to that with BTFC given once in the morning.
- To show whether there will be less 24-hour fluctuation of IOP with the evening dosing of BTFC.
STUDY POPULATION
Consecutive newly-diagnosed, or suitably washed-out patients with exfoliative glaucoma (XFG) who exhibit a mean untreated IOP greater than 25 mm Hg at baseline (10:00).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 39 Years 至 81 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is suffering from XFG (if the patient has bilateral XFG, both eyes will be treated, but the worse eye will be selected for the statistical analysis)
- •Patient is older than 39 years and younger than 85 years
- •Patient is able and willing to participate in the study for the whole duration of the follow up. Will sign the consent form.
- •At screening the untreated IOP at 10:00 (± 1 hr) is greater than 25 mm Hg and lower than 40 mm Hg
- •After bimatoprost run-in therapy the treated IOP at 10:00 (± 1 hr) is greater than 19 mm Hg
排除标准
- 未提供
研究组 & 干预措施
Bimatoprost/Timolol AM therapy
干预措施: Bimatoprost/timolol fixed combination dosed PM (Drug)
Bimatoprost/Timolol PM therapy
干预措施: Bimatoprost/timolol fixed combination dosed PM (Drug)
结局指标
主要结局
Mean 24-hour IOP
时间窗: 3 months of therapy
次要结局
- Side effects with medications(3 months of therapy)
研究者
AGP Konstas
Professor in Ophthalmology
Aristotle University Of Thessaloniki